VIVA BIOTECH HOLDINGS
维亚生物科技控股集团

(Incorporated in the Cayman Islands as an exempted company with limited liability)
(Stock code: 1873)

POSITIVE PROFIT ALERT

The announcement is made by Viva Biotech Holdings (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on its preliminary review of the unaudited consolidated management accounts of the Group, the Group is expected to record (i) an increase of approximately 84% in its revenue for the six months ended June 30, 2019 (the "**Period**") as compared to that for the six months ended June 30, 2018 (the "**Corresponding Period Last Year**"), and (ii) an increase of approximately 47% in net profit excluding extraordinary profit or loss as compared to the Corresponding Period Last Year, of which net profit of the cash-for-service (**CFS**) business registered substantial growth, up approximately 187% from the Corresponding Period Last Year. During the Period, the Group has continuously focused on the development of its CFS and equity-for-service (**EFS**) business models. Such increases were primarily attributable to (i) increase in the number of quality customers and customer orders; (ii) financing and research and development progress of certain of our premium incubation portfolio companies.

The Company is in the process of preparing the unaudited interim results for the Period. The information contained in this announcement is based on a preliminary assessment of the unaudited consolidated management accounts currently available to the Company, which is subject to finalization and other potential adjustments (if any) and has not been reviewed or confirmed by the auditor or the Audit Committee of the Company. Shareholders and potential investors of the Company are advised to refer to the interim results announcement of the Group for the six months ended June 30, 2019, which is expected to be released in late August 2019.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Viva Biotech Holdings
Mao Chen Cheney
Chairman and Chief Executive Officer

Hong Kong, August 14, 2019

As at the date of this announcement, the Board comprises Mr. Mao Chen Cheney, Mr. Wu Ying, Mr. Hua Fengmao and Mr. Ren Delin as executive directors; Ms. Mao Jun and Mr. John Wu Jiong as non-executive directors; and Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang as independent non-executive directors.